Krka Logo

Krka

An international generic pharmaceutical company developing human and animal health products.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto

Description

Krka is an international generic pharmaceutical company engaged in the development, production, marketing, and sales of human and animal health products. The company's core business is focused on generic prescription pharmaceuticals, which it markets under its own brands. Its product portfolio is complemented by a range of non-prescription products and a comprehensive line of animal health products. With a history spanning over 70 years, Krka is committed to providing high-quality, effective, and safe products to a global market, aiming to contribute to a better quality of life.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 12:53
Detailed report on acquisition of treasury shares
English 118.0 KB
2025-12-08 08:30
Detailed report on acquisition of treasury shares
English 127.7 KB
2025-12-08 08:30
Acquisition of treasury shares
English 2.3 KB
2025-12-08 08:30
Podrobno poročilo o nakupih lastnih delnic
English 125.3 KB
2025-12-08 08:30
Pridobivanje lastnih delnic
Slovene 2.2 KB
2025-12-05 08:30
Krka receives new S&P Global CSA Score
English 2.5 KB
2025-12-05 08:30
Krka prejela novo trajnostno bonitetno oceno agencije S&P Global
Slovene 2.5 KB
2025-12-01 08:30
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Pridobivanje lastnih delnic
Slovene 2.1 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.